SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-19-011248
Filing Date
2019-08-28
Accepted
2019-08-28 16:18:17
Documents
14
Period of Report
2019-08-22
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K form8-knewleaseagreeme.htm   iXBRL 8-K 45246
  Complete submission text file 0001628280-19-011248.txt   174926

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20191231.xsd EX-101.SCH 4564
3 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20191231_cal.xml EX-101.CAL 608
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20191231_def.xml EX-101.DEF 1458
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20191231_lab.xml EX-101.LAB 23061
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20191231_pre.xml EX-101.PRE 12040
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-knewleaseagreeme_htm.xml XML 3793
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 191062130
SIC: 2834 Pharmaceutical Preparations